Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Phase 2positiveDivesiranPositive

AI Analysis

Summary

Silence Therapeutics announced positive topline results from its Phase 2 SANRECO trial of divesiran in polycythemia vera, supporting a potential best-in-class profile for the siRNA therapeutic.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Positive topline results from Phase 2 SANRECO trial

Importance:7/10

Sentiment:

0.85

siRNApolycythemia veraPhase 2 datapositive resultsSANRECO trial

Related Companies

$SLN

Read the original article

Published by Drugs.com Clinical Trial Results on August 10, 2026 2:08 AM

Read Original